Liver Cancer Specialty Channel

Liver Cancer

Specialty Channel

FDA Approval

FDA Approves Y-90 Resin Microspheres for Patients With Unresectable Hepatocellular Carcinoma

07/08/2025

Stephanie Holland

Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Based on interim results from...

07/08/2025

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma

07/03/2025

Allison Casey

According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...

According to the TALENTACE...

07/03/2025

Oncology

News

First-Line Anlotinib Plus Penpulimab for Patients With Unresectable Hepatocellular Carcinoma

05/28/2025

Stephanie Holland

According to results from the phase 3 APOLLO trial, first-line anlotinib plus penpulimab significantly improved outcomes compared to anlotinib plus sorafenib among patients with unresectable hepatocellular carcinoma.

According to results from the...

05/28/2025

Oncology

FDA Approval

FDA Approves Nivolumab Plus Ipilimumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma

04/11/2025

Allison Casey

The US Food and Drug Administration has approved nivolumab plus ipilimumab in the first-line setting to treat patients with unresectable or metastatic hepatocellular carcinoma.

The US Food and Drug...

04/11/2025

Oncology

News

Addition of Tiragolumab Shows Promise for Locally Advanced, Unresectable Hepatocellular Carcinoma

02/04/2025

Stephanie Holland

According to results from the phase 1b/2 MORPHEUS-Liver trial, the addition of tiragolumab to atezolizumab plus bevacizumab demonstrated promise among patients with previously untreated locally advanced or unresectable hepatocellular...

According to results from the...

02/04/2025

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Added to TACE Improves Progression-Free Survival for Unresectable Hepatocellular Carcinoma

01/27/2025

Allison Casey

According to a phase 2 study, the addition of camrelizumab and apatinib to transarterial chemoembolization improved the progression-free survival among patients with unresectable hepatocellular carcinoma eligible for embolization.

According to a phase 2 study,...

01/27/2025

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

News

Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers

08/26/2024

Stephanie Holland

According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.

According to results from a...

08/26/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

Conference Coverage

Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma

01/19/2024

Allison Casey

According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.

According to results from the...

01/19/2024

Oncology

News

Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma

01/12/2024

Allison Casey

According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...

According to a retrospective...

01/12/2024

Oncology

News

FDA Approval

FDA Approves Y-90 Resin Microspheres for Patients With Unresectable Hepatocellular Carcinoma

07/08/2025

Stephanie Holland

Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Based on interim results from...

07/08/2025

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma

07/03/2025

Allison Casey

According to the TALENTACE...

07/03/2025

Oncology

News

First-Line Anlotinib Plus Penpulimab for Patients With Unresectable Hepatocellular Carcinoma

05/28/2025

Stephanie Holland

According to results from the...

05/28/2025

Oncology

News

Addition of Tiragolumab Shows Promise for Locally Advanced, Unresectable Hepatocellular Carcinoma

02/04/2025

Stephanie Holland

According to results from the...

02/04/2025

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Added to TACE Improves Progression-Free Survival for Unresectable Hepatocellular Carcinoma

01/27/2025

Allison Casey

According to a phase 2 study,...

01/27/2025

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland

On September 12th, 2024, the US...

09/13/2024

Oncology

News

Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers

08/26/2024

Stephanie Holland

According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.

According to results from a...

08/26/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Results from the ORANGE II PLUS...

05/17/2024

Oncology

Conference Coverage

Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma

01/19/2024

Allison Casey

According to results from the...

01/19/2024

Oncology

News

Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma

01/12/2024

Allison Casey

According to a retrospective...

01/12/2024

Oncology

Interactive Features

Quiz

Quiz: Which options was found to be a potential first-line treatment for hepatocellular carcinoma?

10/17/2022

Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.

Do you know which option was...

10/17/2022

Oncology

Quiz

Quiz: Cabozantinib Plus Atezolizumab for Advanced Hepatocellular Carcinoma

09/02/2022

Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?

Did cabozantinib plus...

09/02/2022

Oncology

Recent News

FDA Approval

FDA Approves Y-90 Resin Microspheres for Patients With Unresectable Hepatocellular Carcinoma

07/08/2025

Stephanie Holland

Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Based on interim results from...

07/08/2025

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma

07/03/2025

Allison Casey

According to the TALENTACE...

07/03/2025

Oncology

News

First-Line Anlotinib Plus Penpulimab for Patients With Unresectable Hepatocellular Carcinoma

05/28/2025

Stephanie Holland

According to results from the...

05/28/2025

Oncology

News

Addition of Tiragolumab Shows Promise for Locally Advanced, Unresectable Hepatocellular Carcinoma

02/04/2025

Stephanie Holland

According to results from the...

02/04/2025

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland

On September 12th, 2024, the US...

09/13/2024

Oncology

News

Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers

08/26/2024

Stephanie Holland

According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.

According to results from a...

08/26/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma

01/12/2024

Allison Casey

According to a retrospective...

01/12/2024

Oncology

News

Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma

08/10/2023

Allison Casey

According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.

According to a randomized trial,...

08/10/2023

Oncology

News

Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies

03/24/2023

Allison Casey

In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.

In this retrospective analysis,...

03/24/2023

Oncology

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology